SCHEMBL30765743

SCHEMBL30765743

COc1ccc(CNc2nc(Cl)c(-c3ccccc3)n(CC(=O)OCc3ccccc3)c2=O)c(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F7 P08709 13/20 0.49
F3 P13726 13/20 0.49
F2 P00734 10/20 0.49
KDM4E B2RXH2 5/20 0.47
ALDH1A1 P00352 5/20 0.47
HPGD P15428 5/20 0.47
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
LMNA P02545 2/20 0.46
POLB P06746 1/20 0.46
CYP1A2 P05177 3/20 0.45
CYP3A4 P08684 3/20 0.45
CYP2C9 P11712 3/20 0.45
TSHR P16473 3/20 0.45
CYP2C19 P33261 3/20 0.45
ALOX15 P16050 2/20 0.45
USP2 O75604 2/20 0.45
CYP2D6 P10635 2/20 0.45
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23460740 0.80 F7 (0.58) F7F3F2PRSS1
SCHEMBL5846880 0.79 F7 (0.61) F7F3F2PRSS1
SCHEMBL14537324 0.78 F2 (0.50) F7F3F2KDM4EALDH1A1
SCHEMBL7912621 0.78 TPSAB1 (0.61) F7F3F2KDM4EALDH1A1
SCHEMBL5847197 0.75 CYP1A2 (0.48) F7F3F2ALDH1A1HPGD
SCHEMBL30765610 0.75 MAPT (0.52) KDM4EALDH1A1HPGDLMNACYP1A2
SCHEMBL23461161 0.74 F7 (0.47) F7F3F2PRSS1
SCHEMBL30765992 0.72 MAPT (0.52) KDM4EALDH1A1HPGDLMNACYP1A2
SCHEMBL5845992 0.72 F7 (0.62) F7F3F2PRSS1
SCHEMBL5164865 0.69 ALDH1A1 (0.45) KDM4EALDH1A1NPSR1POLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed